Compare AbCellera Biologics Inc (ABCL) vs Meta Platforms Inc (META) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Meta Platforms Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Meta Platforms Inc trades at $604.91 (market cap $1.56T). The key difference: Meta Platforms Inc is far larger — about 663.8× AbCellera Biologics Inc's market cap, and Meta Platforms Inc pays a 0.34% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | META | |
|---|---|---|
Market Cap | $2.35B | $1.56T |
Sector | Health | Media |
52-Week High | $8.12 | $790.00 |
52-Week Low | $2.78 | $525.72 |
Enterprise Value | $1.99B | $1.57T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
META trades at $605.36, up 0.84% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 2025 revenue of $201B, net income margin of 32.84%, and improving cash flow trends. Recent AI developments including the Muse Spark launch and positive analyst sentiment support growth prospects despite legal challenges.
META presents a compelling investment case with strong profitability, AI innovation leadership, and analyst consensus pointing to significant upside. Key risks include regulatory lawsuits and high capital expenditures, but the company's financial strength and market position suggest continued growth potential for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
